Basic Information
Zynyz
Regulatory Information
EMEA/H/C/006194
Authorised
April 19, 2024
February 22, 2024
November 29, 2021
Company Information
the netherlands
Paasheuvelweg 25 1105 BP Amsterdam
Incyte Biosciences Distribution B.V.
Drug Classification
Orphan MedicineAdditional Monitoring
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Zynyz is indicated as monotherapy for the first-line treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) not amenable to curative surgery or radiation therapy.
Overview Summary
Incyte Biosciences Distribution B.V. withdrew its application for a marketing authorisation of Zynyz for the treatment of squamous carcinoma of the anal canal, a cancer of the tissues of the anus. The company withdrew the application on 8 October 2021.